<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Ther</journal-id><journal-id journal-id-type="publisher-id">CDTP</journal-id><journal-title-group><journal-title>Cardiovascular Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1755-5914</issn><issn pub-type="epub">1755-5922</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125702</article-id><article-id pub-id-type="pmc">PMC10732976</article-id><article-id pub-id-type="doi">10.1155/2023/8848808</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Ginkgolide B Blocks Vascular Remodeling after Vascular Injury via Regulating Tgf<italic>&#x003b2;</italic>1/Smad Signaling Pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Quan</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ni</surname><given-names>Shuai</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ling</surname><given-names>Li</given-names></name><xref rid="I3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Siqi</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0076-0793</contrib-id><name><surname>Xie</surname><given-names>Hanbin</given-names></name><email>xiehb@sstm.org.cn</email><xref rid="I4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3582-008X</contrib-id><name><surname>Ren</surname><given-names>Zhanhong</given-names></name><email>18211070620@163.com</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Hubei University of Science and Technology, Xianning 437100, China</aff><aff id="I2">
<sup>2</sup>German Cancer Research Center (DKFZ), Heidelberg 69120, Germany</aff><aff id="I3">
<sup>3</sup>School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, China</aff><aff id="I4">
<sup>4</sup>Collections Conservation Research Center, Shanghai Natural History Museum (Branch of Shanghai Science and Technology Museum), Shanghai 200041, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Youakim Saliba</p></fn></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2023</year></pub-date><volume>2023</volume><elocation-id>8848808</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Quan Wang et al.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Coronary artery disease (CAD) is the most prevalent cardiovascular disease worldwide, resulting in myocardial infarction (MI) and even sudden death. Following percutaneous coronary intervention (PCI), restenosis caused by vascular remodeling is always formed at the stent implantation site. Here, we show that Ginkgolide B (GB), a naturally occurring terpene lactone, effectively suppresses vascular remodeling and subsequent restenosis in wild-type mice following left carotid artery (LCA) injury. Additional experiments reveal that GB exerts a protective effect on vascular remodeling and further restenosis through modulation of the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway <italic>in vivo</italic> and in human vascular smooth muscle cells (HVSMAs) but not in human umbilical vein endothelial cells (HUVECs) <italic>in vitro</italic>. Moreover, the beneficial effect of GB is abolished after incubated with pirfenidone (PFD, a drug for idiopathic pulmonary fibrosis, IPF), which can inhibit Tgf<italic>&#x003b2;</italic>1. In Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice, treatment with pirfenidone capsules and Yinxingneizhi Zhusheye (including Ginkgolide B) fails to improve vascular remodeling and restenosis. In conclusion, our data identify that GB could be a potential novel therapeutic agent to block vessel injury-associated vascular remodeling and further restenosis and show significant repression of Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway.</p></abstract><funding-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100017590">Hubei University of Science and Technology</funding-source><award-id>BK202406</award-id></award-group><award-group><funding-source xlink:href="http://dx.doi.org/10.13039/501100003819">Natural Science Foundation of Hubei Province</funding-source><award-id>2022CFB843</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Coronary artery disease (CAD) is the leading cause of mortality worldwide [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>]. Coronary heart disease is characterized by the accumulation of atherosclerotic plaques within the coronary artery wall [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. When these plaques become large, unstable, ruptured, or erosive, it will lead to myocardial infarction (MI) and sudden death [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Percutaneous coronary intervention (PCI) is the most common treatment strategy for coronary heart disease [<xref rid="B7" ref-type="bibr">7</xref>]. Millions of people in worldwide undergo PCI procedures every year. Vascular stent interventional therapy is the main clinical treatment method for cardiovascular diseases, as it causes less trauma and allows for faster recovery [<xref rid="B8" ref-type="bibr">8</xref>]. However, vascular remodeling-induced restenosis and stent thrombosis have become the most important clinical issues after PCI [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>].</p><p>Endothelial cells inevitably experience near-complete damage and loss after stent implantation [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Local blood flow disorder and complex changes in shear stress occur after stent implantation, which alters the phenotype of endothelial cells from static to inflammatory and increases the possibility of thrombosis [<xref rid="B12" ref-type="bibr">12</xref>]. When the intima is severely injured, the smooth muscle cells within the arterial media can migrate into the intima. Neointimal formation and vascular restenosis are caused by the migration, proliferation, and production of connective tissue by vascular smooth muscle cells (VSMCs) [<xref rid="B13" ref-type="bibr">13</xref>]. Transforming growth factor-<italic>&#x003b2;</italic> (Tgf<italic>&#x003b2;</italic>) plays a critical role in biological processes, including the control of cell proliferation and differentiation, the regulation of tissue repair and extracellular matrix accumulation, and the regulation of immune and inflammatory responses [<xref rid="B14" ref-type="bibr">14</xref>]. Previously, studies demonstrated that Tgf<italic>&#x003b2;</italic> has been found to possess proinflammatory, profibrotic, and antiendothelial regeneration abilities [<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Ginkgolide B (GB), a naturally occurring terpene lactone, is an active component extracted from the leaves of Ginkgo biloba [<xref rid="B18" ref-type="bibr">18</xref>]. Previous studies have demonstrated that GB possesses numerous pharmacological properties, including antifibrosis, anti-inflammatory, and antithrombosis activities [<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>]. A mixture of Ginkgolide A, B, and C has undergone phase III clinical studies and has become a preferred natural drug for the treatment of cardiovascular and cerebrovascular diseases [<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>]. GB exhibits stronger inhibition of platelet-activating factor (PAF) [<xref rid="B26" ref-type="bibr">26</xref>]. PAF plays an important role in the process of promoting thrombosis, as it has a unique and strong ability to promote platelet aggregation and release [<xref rid="B27" ref-type="bibr">27</xref>]. Therefore, whether GB can improve vascular remodeling to reduce vessel thrombosis and restenosis and its possible regulatory mechanisms remain unknown.</p><p>The objective of this study was to investigate the function of GB in vascular injury. First, we sought to demonstrate whether treatment with GB could improve vascular remodeling in WT mice following vascular injury. Second, we aimed to identify the underlying mechanism of GB treatment function. Third, we aimed to determine the specific cell lines influenced by GB. Lastly, we aimed to expand the indications of some potential clinical applications of GB.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Reagents</title><p>Ginkgolide B (purity: 98% by HPLC) was supplied by the National Institutes for the Control of Pharmaceutical and Biological Products (Beijing, China). Pirfenidone (Cat number S2907) was obtained from Selleck (Shanghai, China). The drug of Yinxingneizhi Zhusheye (including Ginkgolide B) was obtained from Chengdu Baiyu Pharmaceutical Company. The drug of pirfenidone capsules was purchased from Beijing Continent Pharmaceuticals Company. Tgf<italic>&#x003b2;</italic>1 recombinant protein (Cat number H00007040-P01) was bought from Amyjet Scientific (Wuhan, China). The cell count kit-8 (Cat number CA1210) was bought from Solarbio Life Sciences (Shanghai, China). Rabbit monoclonal to Tgf<italic>&#x003b2;</italic>1 (Cat number ab179695) was obtained from Abcam (CA, USA). Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) (D27F4) Rabbit mAb (Cat number #8828) was applied by Cell Signaling Technology. GAPDH monoclonal antibody (Cat number 60004-1-Ig) was bought from Proteintech (Rosemont, USA).</p></sec><sec id="sec2.2"><title>2.2. Animals and Procedures</title><p>Wild-type C57BL/6&#x02009;J mice were purchased from Liaoning Changsheng biotechnology (Changchun, China). This study was approved by the Animal Ethics Committee of Hubei University of Science and Technology (No. 202204051), China. The homozygous Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> knockout (KO) mice were bought from Cyagen (Suzhou, China). The eight-week-old mice were used to establish the vascular injury model as reported [<xref rid="B28" ref-type="bibr">28</xref>]. In brief, mice were anesthetized with 3% pelltobarbitalum natricum (0.1&#x02009;ml/10&#x02009;g body weight) and then transferred to a warmer pad. Firstly, after depilation of the neck, the skin was cut along the midline of the neck using scissors, and the left carotid artery was exposed by blunt separation with forceps. Subsequently, the left carotid artery and accompanying nerve were bluntly separated under a microscope using microforceps, the proximal end was clamped with a vascular clip, the internal carotid artery was ligated with a 5-0 slip-tie, and the distal end of the external carotid artery was ligated with a 5-0 thread. A metal wire was then inserted from the distal end of the external carotid artery to the left carotid artery and repeated three times to damage the endothelial cells. After that, the metal wire was withdrawn, the bifurcation of the external carotid artery and the internal carotid artery was ligated with 5-0 suture, the slipknot of the internal carotid artery and the vascular clip of the left carotid aorta was released, and the wound was sutured.</p><p>The mice were maintained in a humidity range of (50 &#x000b1; 10)%, temperature of (23 &#x000b1; 2) &#x000b0;C, and a 12-hour light/dark cycle with free access to food and water. The WT mice were randomly distributed into two groups (<italic>n</italic> = 12 each group) and treated for 28 days: (1) vehicle (1% DMSO and 5% carboxymethylcellulose sodium; intragastric administration) treatment group&#x02014;LCA was surgery group, and RCA was corresponding control group; (2) GB (30&#x02009;mg/kg/day; intragastric administration) treatment group&#x02014;LCA was surgery group, and RCA was corresponding control group. The Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice were divided into three groups (<italic>n</italic> = 8 each group) and treated for 28 days: (1) vehicle (1% DMSO and 5% carboxymethylcellulose sodium; intragastric administration) treatment group&#x02014;LCA was surgery group, and RCA was corresponding control group; (2) pirfenidone capsules (72&#x02009;mg/kg/day, calculated from the body surface area of human and mouse; intragastric administration) treatment group&#x02014;LCA was surgery group, and RCA was corresponding control group; (3) Yinxingneizhi Zhusheye (30&#x02009;mg/kg/day; intraperitoneal injection) treatment group&#x02014;LCA was surgery group, and RCA was corresponding control group.</p></sec><sec id="sec2.3"><title>2.3. Echocardiography</title><p>Echocardiography was performed using Vevo 2100 High Resolution Micro Ultrasound System (Visual Sonics, Toronto, Canada) by a blinded researcher as reported previously [<xref rid="B29" ref-type="bibr">29</xref>]. In brief, mice were anesthetized with 3% pelltobarbitalum natricum (0.1&#x02009;ml/10&#x02009;g body weight) and then transferred to an operating platform to remove the neck coat. Next, the Doppler angle was adjusted and optimized, and then, the probe was used to measure blood flow in LCA and RCA.</p></sec><sec id="sec2.4"><title>2.4. Histology</title><p>The method of histology was previously reported [<xref rid="B29" ref-type="bibr">29</xref>]. The isolated LCA and RCA obtained from the mice in all experimental groups were fixated in 4% paraformaldehyde and cryosectioned into a 4&#x02009;<italic>&#x003bc;</italic>m section. Subsequently, the sections were stained with hematoxylin and eosin (H&#x00026;E) and Masson's trichrome. Images were collected using a light microscope (Nikon Corporation), and morphometric analysis was performed using ImageJ software.</p></sec><sec id="sec2.5"><title>2.5. Cell Culture</title><p>The human umbilical vein endothelial cells (HUVECs) were purchased from Mingzhou company (Cat number MZ-5180). The human aorta vascular smooth muscle cells (HVSMCs) were obtained from Mingzhou company (Cat number MZ-2709). The cells were incubated with 10% fetal bovine serum (Gibco Life Technologies, Cat number 10099) and penicillin-streptomycin (Beyotime, Cat number ST488). Subsequently, the cells were cultured in a cell incubator at 37&#x000b0;C with 5% CO<sub>2</sub>.</p></sec><sec id="sec2.6"><title>2.6. Quantitative Real-Time RT-PCR Analysis</title><p>The method of histology was previously reported [<xref rid="B30" ref-type="bibr">30</xref>]. In brief, the total RNA was extracted from tissues and cells using Trizol (Bolaz, Cat number RE0101, Nanjing, China) and reverse transcribed into cDNA by a cDNA Synthesis Kit (Bolaz, Cat number QP0612, Nanjing, China). Quantitative real-time PCR analysis was completed using the SYBR green qPCR mix (low Rox) (Bolaz, Cat number QP0602, Nanjing, China) on 7900 HT Fast Real-Time PCR system (ABI).</p><p>The primers are the following:</p><p>Human <italic>Mcp1</italic>: monocyte chemoattractant protein 1 (NM_002982.4)</p><p>Forward primer: CTCGCTCAGCCAGATGCAAT</p><p>Reverse primer: TTGGGTTTGCTTGTCCAGGT</p><p>Mouse <italic>Mcp1</italic>: monocyte chemoattractant protein 1 (NM_011333.3)</p><p>Forward primer: CACTCACCTGCTGCTACTCA</p><p>Reverse primer: TGAGCTTGGTGACAAAAACTACAG</p><p>Human <italic>Cd68</italic>: cluster of differentiation 68 (NM_001040059.2)</p><p>Forward primer: GGCTACTGGCAGAGAGCAC</p><p>Reverse primer: CTAGTGGTGGCAGGACTGTG</p><p>Mouse <italic>Cd68</italic>: cluster of differentiation 68 (NM_001291058.1)</p><p>Forward primer: AGGACCGCTTATAGCCCAAG</p><p>Reverse primer: TGCCATTTGTGGTGGGAGAA</p><p>Human <italic>&#x003b1;-Sma: &#x003b1;</italic>-smooth muscle actin (NM_001141945.3)</p><p>Forward primer: CTCAACGTGGAGCGCAGT</p><p>Reverse primer: GCTTCACAGGATTCCCGTCT</p><p>Mouse <italic>&#x003b1;-Sma: &#x003b1;</italic>-smooth muscle actin (NM_007392.3)</p><p>Forward primer: CTTCGTGACTACTGCCGAGC</p><p>Reverse primer: AGGTGGTTTCGTGGATGCC</p><p>Human <italic>Tgf&#x003b2;1</italic>: transforming growth factor beta 1 (NM_000660.7)</p><p>Forward primer: TACCTGAACCCGTGTTGCTC</p><p>Reverse primer: CCGGTAGTGAACCCGTTGAT</p><p>Mouse <italic>Tgf&#x003b2;1</italic>: transforming growth factor beta 1 (NM_011577.2)</p><p>Forward primer: ACGTGGAAATCAACGGGATCA</p><p>Reverse primer: GTTGGTATCCAGGGCTCTCC</p></sec><sec id="sec2.7"><title>2.7. Western Blot</title><p>The method was followed as reported [<xref rid="B31" ref-type="bibr">31</xref>]. The proteins were extracted from the tissues (four LCA or RCA samples were pooled into one sample) and cells using radio immunoprecipitation assay lysis buffer (Beyotime, Cat number P0013B) with protease and phosphatase inhibitor cocktail (Beyotime, Cat number P1048). The samples were then separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Subsequently, the membranes were blocked with blocking buffer (Bolaz, Cat number PP1205, Nanjing, China) for 2 hours at room temperature and incubated with primary antibodies overnight at 4&#x000b0;C. The next day, the membranes were washed with phosphate-buffered saline (PBS) three times for 5 minutes and incubated with corresponding secondary antibodies for 2 hours at room temperature. The pictures were obtained from Quantity One (Bio-Rad) and analyzed by ImageJ software.</p></sec><sec id="sec2.8"><title>2.8. Enzyme-Linked Immunosorbent Assays (ELISA)</title><p>The concentration of Tgf<italic>&#x003b2;</italic>1, Mcp1, and <italic>&#x003b1;</italic>-Sma in animal serum and cell culture supernatant were detected by ELISA kit according to the manufacturer's instructions. The ELISA assay kits used were as follows: human transforming growth factor-<italic>&#x003b2;</italic>1 (Tgf<italic>&#x003b2;</italic>1; Cat number JL10706) and mouse transforming growth factor-<italic>&#x003b2;</italic>1 (Tgf<italic>&#x003b2;</italic>1; Cat number JL12223), mouse <italic>&#x003b1;</italic>-smooth muscle actin (<italic>&#x003b1;</italic>-Sma; JL20208), and monocyte chemoattractant protein 1 (Mcp1; Cat number JL20304), all supplied by Jianglai Biology (Shanghai, China).</p></sec><sec id="sec2.9"><title>2.9. Cell Viability Assays</title><p>The cells were seeded into 96-well plates at a density of 2&#x02009;~&#x02009;3 10<sup>3</sup> cells per well and cultured for 36 hours, followed by an assessment of cell viability using a Cell Kit-8 according to the manufacturer's protocols.</p></sec><sec id="sec2.10"><title>2.10. Molecular Docking</title><p>The method was followed as reported [<xref rid="B32" ref-type="bibr">32</xref>]. Docking of Ginkgolide B and Tgf<italic>&#x003b2;</italic>1 was explored using the MOE database via molecular operating environment (MOE v2019.0101, Chemical Computing Group Inc., Montreal, QC, Canada). Following the Protein Data Bank (RCSB Protein Data Bank-RCSB PDB, <ext-link xlink:href="http://www.pdb.org/" ext-link-type="uri">http://www.pdb.org/</ext-link>), we got the Tgf<italic>&#x003b2;</italic>1 protein structure data with structure ID 3TZM.</p></sec><sec id="sec2.11"><title>2.11. Statistical Analysis</title><p>The data were analyzed using GraphPad Prism 8.0.1 and expressed as mean &#x000b1; standard error of mean (SEM). The data were judged to be statistically significant when <italic>P</italic> was &#x0003c;0.05. Two-tailed Student's <italic>t</italic>-tests or one-way analysis of variance (ANOVA) was used to analyze data.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Ginkgolide B Improves Vascular Remodeling and Inflammation after Vessel Injury</title><p>Clinically, after PCI procedures are performed to treat blocked blood vessels in patients, severe restenosis often occurs at the site of stent implantation due to vascular remodeling one year postprocedures, representing a significant threat to the patient's life safety. To explore the function of Ginkgolide B (GB) in vascular remodeling and its potential impact on restenosis formation, a wire injury model was established in murine left carotid artery (LCA), which the right carotid artery (RCA) of the same murine served as a control group (<xref rid="fig1" ref-type="fig">Figure 1(a)</xref>). After treatment with GB (30&#x02009;mg/kg/day) by intragastric administration for 28 days, a serious of detections were performed. The Doppler echocardiography revealed a significantly decreased blood flow velocity in the LCA compared with the corresponding RCA (<xref rid="fig1" ref-type="fig">Figure 1(b)</xref>). After GB treatment, the blood flow velocity was markedly increased in wire-injured LCA than vehicle treatment group (<xref rid="fig1" ref-type="fig">Figure 1(b)</xref>). GB treatment did not significantly affect RCA blood flow nor did vehicle treatment (<xref rid="fig1" ref-type="fig">Figure 1(b)</xref>). H&#x00026;E staining revealed that the carotid artery walls of LCA were markedly thickened, and the intimal thickness and medial thickness were significantly increased compared to RCA after LCA injury, indicating vessel remodeling (Figures <xref rid="fig1" ref-type="fig">1(c)</xref> and <xref rid="fig1" ref-type="fig">1(e)</xref>). However, the vessel remodeling phenotypes of LCA were significantly improved after treatment with GB (Figures <xref rid="fig1" ref-type="fig">1(c)</xref> and <xref rid="fig1" ref-type="fig">1(e)</xref>). Furthermore, Masson's staining demonstrated that the fibrosis is significantly upregulated in the LCA compared to the RCA, and GB treatment significantly downregulated fibrosis in the RCA compared to vehicle treatment of the LCA (Figures <xref rid="fig1" ref-type="fig">1(d)</xref> and <xref rid="fig1" ref-type="fig">1(f)</xref>). Additionally, the mRNA expression levels of <italic>Mcp1</italic> (monocyte chemoattractant protein 1, marker for inflammation), <italic>Cd68</italic> (cluster of differentiation 68, marker for macrophage infiltration), and <italic>&#x003b1;-Sma</italic> (<italic>&#x003b1;</italic>-Smooth muscle actin, marker for VSMC proliferation) were significantly upregulated in LCA compared to RCA (<xref rid="fig1" ref-type="fig">Figure 1(g)</xref>). Moreover, mice treated with GB exhibited a significant inhibition in the expression of <italic>Mcp1</italic>, <italic>Cd68</italic>, and <italic>&#x003b1;-Sma</italic> in the LCA (<xref rid="fig1" ref-type="fig">Figure 1(g)</xref>). These data revealed that fibrosis, inflammation, infiltration, and VSMC proliferation were significantly increased in LCA compared to RCA. In conclusion, GB treatment plays a critical role in attenuating vascular modeling and further restenosis induced by vessel injury.</p></sec><sec id="sec3.2"><title>3.2. Ginkgolide B Plays a Protective Role in Vascular Injury by Tgf<italic>&#x003b2;</italic>1/Smad Signal Pathway</title><p>Previously, studies demonstrated that Tgf<italic>&#x003b2;</italic>1 plays a key role in fibrosis, inflammation, and VSMC proliferation [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. We hypothesized that the protective function of GB in vascular remodeling is performed by regulating the Tgf<italic>&#x003b2;</italic>1 signal pathway. Western blotting showed that the protein levels of Tgf<italic>&#x003b2;</italic>1 and phosphorylated Smad2/3 (p-Smad2/3) were notably increased in murine-injured LCA compared with murine RCA (<xref rid="fig2" ref-type="fig">Figure 2(a)</xref>). Additionally, GB treatment significantly reduced Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 expressions at the protein level compared with vehicle treatment in the LCA group (<xref rid="fig2" ref-type="fig">Figure 2(a)</xref>). Similar to the results at the protein level, the mRNA expression of Tgf<italic>&#x003b2;</italic>1 was markedly upregulated after LCA vessel injury, and this upregulation was repressed by GB treatment (<xref rid="fig2" ref-type="fig">Figure 2(b)</xref>). Furthermore, the levels of Tgf<italic>&#x003b2;</italic>1 in mouse serum were found to have similar sequences (<xref rid="fig2" ref-type="fig">Figure 2(c)</xref>). When we detected the levels of Mcp1 and <italic>&#x003b1;</italic>-Sma in mouse serum, we found that these were greatly elevated in the LCA and were dramatically downregulated after GB treatment (<xref rid="fig2" ref-type="fig">Figure 2(d)</xref>). Taken together, these findings demonstrate that GB exhibits a protective role in vascular remodeling by Tgf<italic>&#x003b2;</italic>1/Smad signal pathway.</p></sec><sec id="sec3.3"><title>3.3. Ginkgolide B Has No Influence of Tgf<italic>&#x003b2;</italic>1/Smad Signal Pathway in Human Umbilical Vein Endothelial Cells (HUVECs)</title><p>Vascular remodeling and further restenosis are primarily caused by the proliferation and migration of endothelial cells or VSMCs [<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>]. To further confirm the underlying mechanism of GB <italic>in vitro</italic>, a Tgf<italic>&#x003b2;</italic>1-stimulated HUVEC model was first established. Previously, articles have demonstrated that 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 could significantly upregulate the expression of Tgf<italic>&#x003b2;</italic>1 <italic>in vitro</italic> [<xref rid="B41" ref-type="bibr">41</xref>]. After being incubated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 15&#x02009;min, 30&#x02009;min, and 60&#x02009;min in HUVECs, the protein levels of Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 were detected by western blot (<xref rid="fig3" ref-type="fig">Figure 3(a)</xref>). The results showed that Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 were obviously increased after incubated for 60&#x02009;min compared with the control group (<xref rid="fig3" ref-type="fig">Figure 3(a)</xref>). Then, the cytotoxic effects of GB at different doses on HUVECs were assessed using the cell counting kit-8. GB at the low concentrations (10, 20, 40, and 80&#x02009;<italic>&#x003bc;</italic>M) had no significant cytotoxic effect on HUVECs, while 150 and 300&#x02009;<italic>&#x003bc;</italic>M of GB resulted in a sharp reduction in cell viability compared with the control group, indicating that a low concentration of 40&#x02009;<italic>&#x003bc;</italic>M GB was suitable for performing other experiments (<xref rid="fig3" ref-type="fig">Figure 3(b)</xref>). Then, HUVECs were incubated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min, and GB were added to treat HUVECs for 2 hours. We also measured the level of Tgf<italic>&#x003b2;</italic>1 in the supernatant cell culture, which also demonstrated that GB had no effect on adjusting the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway (<xref rid="fig3" ref-type="fig">Figure 3(c)</xref>). Additionally, the western blot revealed that GB could not regulate the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway in HUVECs regardless of whether they were stimulated with TGF-<italic>&#x003b2;</italic>1 (<xref rid="fig3" ref-type="fig">Figure 3(d)</xref>). These findings indicated that GB has no influence on the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway in HUVECs.</p></sec><sec id="sec3.4"><title>3.4. Ginkgolide B Regulates Tgf<italic>&#x003b2;</italic>1/Smad Signal Pathway in Human Vascular Smooth Muscle Cells (HVSMAs)</title><p>To further determine whether GB plays a protective role in HVSMCs through the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway, TGF-<italic>&#x003b2;</italic>1 concentration-dependent experiments and HVSMA viability assays were conducted (Figures <xref rid="fig4" ref-type="fig">4(a)</xref> and <xref rid="fig4" ref-type="fig">4(b)</xref>). These results repeatedly showed that 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 incubated for 60&#x02009;min and 40&#x02009;<italic>&#x003bc;</italic>M GB treatment were optimal (Figures <xref rid="fig4" ref-type="fig">4(a)</xref> and <xref rid="fig4" ref-type="fig">4(b)</xref>). HVSMAs were stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min and then treated with GB for 2 hours. The Tgf<italic>&#x003b2;</italic>1 level in supernatant cell cultures was significantly repressed after GB treatment (<xref rid="fig3" ref-type="fig">Figure 3(c)</xref>). Additionally, the western blot revealed that the protein levels of Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 were obviously decreased by GB treatment in HVSMCs (<xref rid="fig3" ref-type="fig">Figure 3(d)</xref>). Collectively, these findings suggest that GB exerts a protective effect on HVSMAs by inhibiting the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway.</p></sec><sec id="sec3.5"><title>3.5. The Protective Role of Ginkgolide B Is Abolished after Incubated with Tgf<italic>&#x003b2;</italic>1 Inhibitor in HVSMAs</title><p>To further confirm the inhibitory effect of GB on Tgf<italic>&#x003b2;</italic>1, pirfenidone (PFD), a Tgf<italic>&#x003b2;</italic>1 inhibitor, was applied to verify the function of GB. Firstly, HVSMAs were incubated with different concentrations of pirfenidone for 2 hours to identify a feasible concentration range (<xref rid="fig5" ref-type="fig">Figure 5(a)</xref>). The western blot revealed that the expression of Tgf<italic>&#x003b2;</italic>1 was significantly repressed by pirfenidone, and p-Smad2/3 was also obviously decreased (<xref rid="fig5" ref-type="fig">Figure 5(a)</xref>). Then, we further detected the suppressive function of pirfenidone on TGF-<italic>&#x003b2;</italic>1 stimulated (<xref rid="fig5" ref-type="fig">Figure 5(b)</xref>). The results showed that after being stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min, pirfenidone concentrations greater than 1&#x02009;<italic>&#x003bc;</italic>g/ml could play a repressive role in Tgf<italic>&#x003b2;</italic>1 and downstream p-Smad2/3 at the protein level (<xref rid="fig5" ref-type="fig">Figure 5(b)</xref>). In addition, after being incubated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min, 1&#x02009;<italic>&#x003bc;</italic>g/ml pirfenidone and 40&#x02009;<italic>&#x003bc;</italic>M GB were applied to treat HVSMAs for 2 hours (<xref rid="fig5" ref-type="fig">Figure 5(c)</xref>). We found that treatment with pirfenidone significantly decreased Tgf<italic>&#x003b2;</italic>1 and subsequent p-Smad2/3 levels, regardless of whether the cells were stimulated with TGF-<italic>&#x003b2;</italic>1, but treatment with GB did not affect these levels when no TGF-<italic>&#x003b2;</italic>1 stimulation was present (<xref rid="fig5" ref-type="fig">Figure 5(c)</xref>). Following stimulation with TGF-<italic>&#x003b2;</italic>1, treatment with either pirfenidone or GB alone repressed the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway, but the inhibitory ability of GB was obviously weaker than that of pirfenidone (<xref rid="fig5" ref-type="fig">Figure 5(c)</xref>). However, when treated with a combination of pirfenidone and GB, the restrictive ability of the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway was approximately equivalent to that of a single treatment with pirfenidone alone, indicating that the function of GB on the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway was replaced by the stronger inhibitor pirfenidone (<xref rid="fig5" ref-type="fig">Figure 5(c)</xref>). Interestingly, the detection of Tgf<italic>&#x003b2;</italic>1 in supernatant cell cultures was consistent with the protein expression outcomes (<xref rid="fig5" ref-type="fig">Figure 5(d)</xref>). In conclusion, these results revealed that the suppressive function of GB on the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway is abolished by treatment with the Tgf<italic>&#x003b2;</italic>1 inhibitor pirfenidone.</p></sec><sec id="sec3.6"><title>3.6. The Protective Function of Ginkgolide B in Vessel Remodeling and Inflammation Caused by Vascular Injury Is Vanished in Tgf<italic>&#x003b2;</italic>1 Knockout Mice</title><p>Conclusively, the beneficial function of GB <italic>in vivo</italic> (wild-type mice) and <italic>in vitro</italic> (HVSMAs) was both confirmed by regulating the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway. The drug pirfenidone capsules used to treat idiopathic pulmonary fibrosis by decreasing the expression of Tgf<italic>&#x003b2;</italic>1 and the drug Yinxingneizhi Zhusheye (including Ginkgolide B) were used to identify whether GB played a protective role in vascular remodeling by regulating the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway. Hence, the Tgf<italic>&#x003b2;</italic>1 knockout mice (Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup>) were subjected to LCA injury by wire and treated with Yinxingneizhi Zhusheye (30&#x02009;mg/kg/day; intraperitoneal injection) and pirfenidone capsules (72&#x02009;mg/kg/day; intragastric administration) for 28 days (<xref rid="fig6" ref-type="fig">Figure 6(a)</xref>). The Doppler echocardiography showed that in Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice, the blood flow velocity in LCA was significantly decreased after vascular injury, and treatment with pirfenidone capsules and Yinxingneizhi Zhusheye did not improve blood flow velocity (Figures <xref rid="fig6" ref-type="fig">6(b)</xref> and <xref rid="fig6" ref-type="fig">6(e)</xref>). H&#x00026;E staining revealed that the vessel remodeling was also present in the LCA of Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice, indicating that the neointimal formation is not solely dependent on the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway (<xref rid="fig6" ref-type="fig">Figure 6(c)</xref>), but the vessel was not entire blocked compared to WT mice (<xref rid="fig1" ref-type="fig">Figure 1(c)</xref>). The indices of vessel remodeling were quantified, showing that the carotid artery walls of the LCA were markedly thickened, and the intimal thickness and medial thickness were obviously increased after LCA injury in Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice (Figures <xref rid="fig6" ref-type="fig">6(c)</xref> and <xref rid="fig6" ref-type="fig">6(f)</xref>). Notably, there was no obvious improvement in vessel remodeling in the LCA of Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice treated with pirfenidone capsules and Yinxingneizhi Zhusheye (Figures <xref rid="fig6" ref-type="fig">6(c)</xref> and <xref rid="fig6" ref-type="fig">6(f)</xref>). Moreover, aortic collagen deposition was detected by Masson's staining. The results showed that the collagen deposition in the LCA was significantly enhanced in Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice after vascular injury (Figures <xref rid="fig6" ref-type="fig">6(d)</xref> and <xref rid="fig6" ref-type="fig">6(g)</xref>). Similarly, pirfenidone capsules and Yinxingneizhi Zhusheye were unable to effectively repress collagen formation (Figures <xref rid="fig6" ref-type="fig">6(d)</xref> and <xref rid="fig6" ref-type="fig">6(g)</xref>). The mRNA expressions of <italic>Mcp1</italic>, <italic>Cd68</italic>, and <italic>&#x003b1;-Sma</italic> in the LCA of Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice were both significantly increased compared to the corresponding group (<xref rid="fig6" ref-type="fig">Figure 6(h)</xref>). The inflammation and macrophage infiltration in the LCA of Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice could not be attenuated by pirfenidone capsules and Yinxingneizhi Zhusheye (<xref rid="fig6" ref-type="fig">Figure 6(h)</xref>). Taken together, these results demonstrated that the protective effect of GB on vascular remodeling and further restenosis is abolished after reducing the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway.</p></sec><sec id="sec3.7"><title>3.7. The Molecular Docking of Ginkgolide B and Tgf<italic>&#x003b2;</italic>1</title><p>Although these results demonstrated that Ginkgolide B could regulate Tgf<italic>&#x003b2;</italic>1, the underlying regulation mechanism is unknown. To further resolve the question, we suspected that Ginkgolide B could bind with Tgf<italic>&#x003b2;</italic>1 to competitively reduce the bind of Tgf<italic>&#x003b2;</italic>1 and its receptor. According to the molecular docking results, Tgf<italic>&#x003b2;</italic>1 has four sites that can form hydrogen bonds with Ginkgolide B. These four sites are ASP 290, LYS 213, ILE 21, and SER 287, with corresponding distances and energies (kcal/mol) of 2.67 and -1.9, 2.67 and -1.5, 3.49 and -0.9, and 2.99 and -0.6, respectively (<xref rid="fig7" ref-type="fig">Figure 7</xref>). These results indicate that there is a certain binding ability between Tgf<italic>&#x003b2;</italic>1 and Ginkgolide B.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>In this study, we demonstrated that the GB treatment downregulates the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway, exerting a protective role in vascular remodeling and further restenosis (<xref rid="fig8" ref-type="fig">Figure 8</xref>). Specifically, we found that vascular remodeling and restenosis are severe after LCA injury by wire but are obviously improved by GB treatment (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The experiments <italic>in vivo</italic> showed that the beneficial improvement of GB on vascular remodeling and restenosis is due to its regulation of the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway (Figures <xref rid="fig1" ref-type="fig">1</xref> and <xref rid="fig2" ref-type="fig">2</xref>). Next, cell experiments demonstrated that GB could repress the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway in HVSMCs but not HUVECs (Figures <xref rid="fig3" ref-type="fig">3</xref> and <xref rid="fig4" ref-type="fig">4</xref>). When incubated with pirfenidone, an inhibitor of Tgf<italic>&#x003b2;</italic>1, the function of GB is abolished (<xref rid="fig5" ref-type="fig">Figure 5</xref>). Moreover, in Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice, pirfenidone capsules and Yinxingneizhi Zhusheye do not exert a beneficial effect on vascular remodeling and restenosis after LCA injury (<xref rid="fig6" ref-type="fig">Figure 6</xref>).</p><p>In the next 30 years, the number of people beyond 65 will double, and chronic inflammation is one of the important causes of natural aging [<xref rid="B42" ref-type="bibr">42</xref>]. Vascular remodeling induced by chronic inflammation is particularly important for the body, as it can lead to various vascular diseases such as vascular remodeling, embolism, and atherosclerosis [<xref rid="B42" ref-type="bibr">42</xref>]. In this study, we demonstrated Ginkgolide B as a novel candidate drug of vascular inflammation and remodeling associated with vessel injury. Our data showed that GB could significantly suppress vascular inflammation and remodeling by regulating the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway in HVSMCs. We propose that Tgf <italic>&#x003b2;</italic>1 has a promoting effect on vascular inflammation and remodeling, while GB is a natural Tgf<italic>&#x003b2;</italic>1 antagonist, which can reduce vascular inflammation and remodeling caused by vascular injury.</p><p>Due to the influence of bad diet, lifestyle, or heredity, blood vessel stenosis or partial heart disease can lead to insufficient blood supply [<xref rid="B43" ref-type="bibr">43</xref>]. At present, the clinical application of stent implantation primarily focuses on addressing severely occluded vessels and restoring normal blood supply. Although modern stents have been upgraded from metal stents to drug elution stents, including antiplatelet aggregation drugs such as aspirin and other drugs to reduce thrombosis and restenosis, the possibility of restenosis still exists [<xref rid="B44" ref-type="bibr">44</xref>]. In addition, patients still need to take antiplatelet drugs such as aspirin and clopidogrel for a long time, but the side effects can be serious. These include allergic reactions, gastrointestinal discomfort, and hypersensitivity reactions, which can lead to poor compliance with medication. In this study, we found that the existing clinical drugs, ginkgolide injection and pirfenidone capsule, can significantly reduce vascular inflammation and vascular remodeling caused by vascular injury. Our study provides some basic support for expanding the indications of Yinxingneizhi Zhusheye and pirfenidone capsule in clinical practice.</p><p>Interestingly, the study found that GB could regulate the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway in HVSMCs, not in HUVECs. Numerous studies have shown that the LAP-Tgf<italic>&#x003b2;</italic>1 in the extracellular matrix cleave to mature Tgf<italic>&#x003b2;</italic>1 under certain stimuli and bind to Tgf<italic>&#x003b2;</italic>1 receptors on the membrane, leading to phosphorylation of Smad2/3 in the cytoplasm and nuclear entry, promoting transcription of inflammatory factors [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B45" ref-type="bibr">45</xref>]. GB acts on smooth muscle cells but not endothelial cells. We speculate that this is due to the different receptors present on the cell membranes of the two cells. Da et al. found that AGGF1 acts on the integrin <italic>&#x003b1;</italic>7 receptor on the smooth muscle cell membrane, enhancing the interaction between integrin <italic>&#x003b1;</italic>7 and Tgf<italic>&#x003b2;</italic>1, thereby inhibiting cleavage of LAP-Tgf<italic>&#x003b2;</italic>1 and production of mature Tgf<italic>&#x003b2;</italic>1, leading to reduced gene transcription involved in vascular inflammation and remodeling, whereas this therapeutic effect is ineffective in endothelial cells, and the author hypothesizes that this is due to some problems with the binding of AGGF1 and integrin a5 receptors on the membrane of endothelial cells [<xref rid="B29" ref-type="bibr">29</xref>]. This is indeed a question worth exploring. In different diseases, different cells play completely different roles. After stent implantation, due to friction between the stent and the blood vessel wall, endothelial cells on the vessel wall are damaged or even disappear [<xref rid="B46" ref-type="bibr">46</xref>]. The barrier function of endothelial cells is to smooth blood flow through the vessel. When they are damaged, inflammatory factors and adhesion substances in the blood accumulate to form thrombi. At the same time, smooth muscle cells proliferate, which decreases the elasticity of the blood vessel wall and narrows the lumen. The role of GB on smooth muscle cells is precisely the right response to the condition of blood vessels after stent implantation.</p><p>GB effectively inhibits the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway, thereby reducing vascular remodeling and the recurrence of vascular stenosis. However, following LCA vascular injury in Tgf<italic>&#x003b2;</italic>1<sup>&#x02212;/&#x02212;</sup> mice, the neointimal and vascular remodeling also occurred but was less severe than in wild-type mice, indicating that vascular remodeling and further restenosis are not only dependent on the Tgf<italic>&#x003b2;</italic>1/Smad signaling pathway. Previously, studies showed that the Notch signal pathway [<xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>], micro-RNA [<xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>], and AMPK/mTOR signaling pathway [<xref rid="B53" ref-type="bibr">53</xref>] all play varying roles in the process of vascular remodeling. Therefore, GB likely needs to be combined with other agents to effectively treat vascular remodeling.</p><p>Interestingly, our study found that the drug of pirfenidone capsules also has a protective function in vascular remodeling diseases apart from idiopathic pulmonary fibrosis.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>In summary, the present study demonstrates the beneficial effect of GB on anti-inflammation, antifibrosis, antimacrophage infiltration, and vascular remodeling after vascular injury. Our study also demonstrates that the vascular remodeling and restenosis could not be completely abolished by suppressing Tgf<italic>&#x003b2;</italic>1. Additionally, we have broadened the indication of pirfenidone capsules and Yinxingneizhi Zhusheye for vascular remodeling disease. Finally, our data identify GB as a novel candidate drug for developing strategies to decrease vascular remodeling and prevent the recurrence of stenosis, which could potentially be used for the treatment of atherosclerosis and CAD.</p></sec></body><back><ack><title>Acknowledgments</title><p>We appreciated Dr. Xin Wang's significant contributions to the data statistical analysis. This study was supported by the Natural Science Foundation of Hubei Province (Grant No. 2022CFB843) and the Hubei University of Science and Technology School-level Fund (No. BK202406).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding authors upon request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec><sec><title>Authors' Contributions</title><p>Quan Wang and Shuai Ni contributed equally to this study.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material id="supp-1" position="float" content-type="local-data"><label>Supplementary Materials</label><caption><p>Additional statistical data are given in the supplementary material, including original western blot and statistical data.</p></caption><media xlink:href="8848808.f1.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>G. Q.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Girelli</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>An <italic>LRP8</italic> variant is associated with familial and premature coronary artery disease and myocardial infarction</article-title><source>
<italic>American Journal of Human Genetics</italic>
</source><year>2007</year><volume>81</volume><issue>4</issue><fpage>780</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1086/521581</pub-id><pub-id pub-id-type="other">2-s2.0-35349013508</pub-id><pub-id pub-id-type="pmid">17847002</pub-id>
</element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Molecular genetics of coronary artery disease</article-title><source>
<italic>Current Opinion in Cardiology</italic>
</source><year>2005</year><volume>20</volume><issue>3</issue><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1097/01.hco.0000160373.77190.f1</pub-id><pub-id pub-id-type="other">2-s2.0-18944399174</pub-id><pub-id pub-id-type="pmid">15861005</pub-id>
</element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Advances in the genetic basis of coronary artery disease</article-title><source>
<italic>Current Atherosclerosis Reports</italic>
</source><year>2005</year><volume>7</volume><issue>3</issue><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1007/s11883-005-0012-6</pub-id><pub-id pub-id-type="other">2-s2.0-20444424537</pub-id><pub-id pub-id-type="pmid">15811259</pub-id>
</element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Libby</surname><given-names>P.</given-names></name>
<name><surname>Theroux</surname><given-names>P.</given-names></name>
</person-group><article-title>Pathophysiology of coronary artery disease</article-title><source>
<italic>Circulation</italic>
</source><year>2005</year><volume>111</volume><issue>25</issue><fpage>3481</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.537878</pub-id><pub-id pub-id-type="other">2-s2.0-21544467275</pub-id><pub-id pub-id-type="pmid">15983262</pub-id>
</element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roifman</surname><given-names>I.</given-names></name>
<name><surname>Therrien</surname><given-names>J.</given-names></name>
<name><surname>Ionescu-Ittu</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Coarctation of the aorta and coronary artery disease</article-title><source>
<italic>Circulation</italic>
</source><year>2012</year><volume>126</volume><issue>1</issue><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.088294</pub-id><pub-id pub-id-type="other">2-s2.0-84863628710</pub-id><pub-id pub-id-type="pmid">22675158</pub-id>
</element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Libby</surname><given-names>P.</given-names></name>
</person-group><article-title>Inflammation in atherosclerosis</article-title><source>
<italic>Nature</italic>
</source><year>2002</year><volume>420</volume><issue>6917</issue><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1038/nature01323</pub-id><pub-id pub-id-type="other">2-s2.0-0037180771</pub-id><pub-id pub-id-type="pmid">12490960</pub-id>
</element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faxon</surname><given-names>D. P.</given-names></name>
<name><surname>Williams</surname><given-names>D. O.</given-names></name>
</person-group><article-title>Interventional cardiology: current status and future directions in coronary disease and valvular heart disease</article-title><source>
<italic>Circulation</italic>
</source><year>2016</year><volume>133</volume><issue>25</issue><fpage>2697</fpage><lpage>2711</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.02355</pub-id><pub-id pub-id-type="pmid">27324364</pub-id>
</element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baibhav</surname><given-names>B.</given-names></name>
<name><surname>Gedela</surname><given-names>M.</given-names></name>
<name><surname>Moulton</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Role of invasive functional assessment in surgical revascularization of coronary artery disease</article-title><source>
<italic>Circulation</italic>
</source><year>2018</year><volume>137</volume><issue>16</issue><fpage>1731</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031182</pub-id><pub-id pub-id-type="other">2-s2.0-85053796345</pub-id><pub-id pub-id-type="pmid">29661951</pub-id>
</element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havele</surname><given-names>C.</given-names></name>
<name><surname>Paetkau</surname><given-names>V.</given-names></name>
</person-group><article-title>Cyclosporine blocks the activation of antigen-dependent cytotoxic T lymphocytes directly by an IL-2-independent mechanism</article-title><source>
<italic>Journal of Immunology</italic>
</source><year>1988</year><volume>140</volume><issue>10</issue><fpage>3303</fpage><lpage>3308</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.140.10.3303</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Autar</surname><given-names>A.</given-names></name>
<name><surname>Taha</surname><given-names>A.</given-names></name>
<name><surname>van Duin</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Endovascular procedures cause transient endothelial injury but do not disrupt mature neointima in drug eluting stents</article-title><source>
<italic>Scientific Reports</italic>
</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>p. 2173</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-58938-z</pub-id><pub-id pub-id-type="pmid">32034227</pub-id>
</element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavlides</surname><given-names>S.</given-names></name>
<name><surname>Gutierrez-Pajares</surname><given-names>J. L.</given-names></name>
<name><surname>Iturrieta</surname><given-names>J.</given-names></name>
<name><surname>Lisanti</surname><given-names>M. P.</given-names></name>
<name><surname>Frank</surname><given-names>P. G.</given-names></name>
</person-group><article-title>Endothelial caveolin-1 plays a major role in the development of atherosclerosis</article-title><source>
<italic>Cell and Tissue Research</italic>
</source><year>2014</year><volume>356</volume><issue>1</issue><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s00441-013-1767-7</pub-id><pub-id pub-id-type="other">2-s2.0-84898877229</pub-id><pub-id pub-id-type="pmid">24390341</pub-id>
</element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frank</surname><given-names>P. G.</given-names></name>
<name><surname>Pavlides</surname><given-names>S.</given-names></name>
<name><surname>Lisanti</surname><given-names>M. P.</given-names></name>
</person-group><article-title>Caveolae and transcytosis in endothelial cells: role in atherosclerosis</article-title><source>
<italic>Cell and Tissue Research</italic>
</source><year>2009</year><volume>335</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s00441-008-0659-8</pub-id><pub-id pub-id-type="other">2-s2.0-57749189130</pub-id><pub-id pub-id-type="pmid">18688651</pub-id>
</element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cooke</surname><given-names>J. P.</given-names></name>
</person-group><article-title>Flow, NO, and atherogenesis</article-title><source>
<italic>Proceedings of the National Academy of Sciences of the United States of America</italic>
</source><year>2003</year><volume>100</volume><issue>3</issue><fpage>768</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1073/pnas.0430082100</pub-id><pub-id pub-id-type="other">2-s2.0-0037417964</pub-id><pub-id pub-id-type="pmid">12552094</pub-id>
</element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N. N.</given-names></name>
<name><surname>Ramji</surname><given-names>D. P.</given-names></name>
</person-group><article-title>The role of transforming growth factor-<italic>&#x003b2;</italic> in atherosclerosis</article-title><source>
<italic>Cytokine &#x00026; Growth Factor Reviews</italic>
</source><year>2006</year><volume>17</volume><issue>6</issue><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2006.09.002</pub-id><pub-id pub-id-type="other">2-s2.0-33751252267</pub-id><pub-id pub-id-type="pmid">17056295</pub-id>
</element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feinberg</surname><given-names>M. W.</given-names></name>
<name><surname>Jain</surname><given-names>M. K.</given-names></name>
</person-group><article-title>Role of transforming growth factor-beta1/Smads in regulating vascular inflammation and atherogenesis</article-title><source>
<italic>Panminerva Medica</italic>
</source><year>2005</year><volume>473</volume><fpage>169</fpage><lpage>186</lpage></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feinberg</surname><given-names>M. W.</given-names></name>
<name><surname>Shimizu</surname><given-names>K.</given-names></name>
<name><surname>Lebedeva</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation</article-title><source>
<italic>Circulation Research</italic>
</source><year>2004</year><volume>94</volume><issue>5</issue><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000119170.70818.4F</pub-id><pub-id pub-id-type="other">2-s2.0-12144289322</pub-id><pub-id pub-id-type="pmid">14752027</pub-id>
</element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>P.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Transforming growth factor <italic>&#x003b2;</italic>1 suppresses proinflammatory gene program independent of its regulation on vascular smooth muscle differentiation and autophagy</article-title><source>
<italic>Cellular Signalling</italic>
</source><year>2018</year><volume>50</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2018.07.002</pub-id><pub-id pub-id-type="other">2-s2.0-85050088328</pub-id><pub-id pub-id-type="pmid">30006123</pub-id>
</element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maclennan</surname><given-names>K. M.</given-names></name>
<name><surname>Darlington</surname><given-names>C. L.</given-names></name>
<name><surname>Smith</surname><given-names>P. F.</given-names></name>
</person-group><article-title>The CNS effects of <italic>Ginkgo biloba</italic> extracts and ginkgolide B</article-title><source>
<italic>Progress in Neurobiology</italic>
</source><year>2002</year><volume>67</volume><issue>3</issue><fpage>235</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0301-0082(02)00015-1</pub-id><pub-id pub-id-type="other">2-s2.0-0036343060</pub-id><pub-id pub-id-type="pmid">12169298</pub-id>
</element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>Y. X.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>G. G.</given-names></name>
</person-group><article-title>Cardiac dysfunction is attenuated by ginkgolide B via reducing oxidative stress and fibrosis in diabetic rats</article-title><source>
<italic>Iranian Journal of Basic Medical Sciences</italic>
</source><year>2020</year><volume>238</volume><fpage>1078</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.22038/ijbms.2020.44210.10358</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Bao</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Qi</surname><given-names>R.</given-names></name>
</person-group><article-title>Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice</article-title><source>
<italic>PLoS One</italic>
</source><year>2012</year><volume>7</volume><issue>5, article e36237</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0036237</pub-id><pub-id pub-id-type="other">2-s2.0-84861006695</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Thrombus inhibition and neuroprotection for ischemic stroke treatment through platelet regulation and ROS scavenging</article-title><source>
<italic>ChemMedChem</italic>
</source><year>2022</year><volume>17</volume><issue>24, article e202200317</issue><pub-id pub-id-type="doi">10.1002/cmdc.202200317</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esposito</surname><given-names>M.</given-names></name>
<name><surname>Carotenuto</surname><given-names>M.</given-names></name>
</person-group><article-title>Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study</article-title><source>
<italic>Neurological Sciences</italic>
</source><year>2011</year><volume>32</volume><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s10072-010-0411-5</pub-id><pub-id pub-id-type="other">2-s2.0-79551609816</pub-id><pub-id pub-id-type="pmid">20872034</pub-id>
</element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woelkart</surname><given-names>K.</given-names></name>
<name><surname>Feizlmayr</surname><given-names>E.</given-names></name>
<name><surname>Dittrich</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three differentGinkgo bilobaL. preparations in humans</article-title><source>
<italic>Phytotherapy Research</italic>
</source><year>2010</year><volume>24</volume><issue>3</issue><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1002/ptr.3074</pub-id><pub-id pub-id-type="other">2-s2.0-77349104616</pub-id><pub-id pub-id-type="pmid">20041430</pub-id>
</element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wittwer</surname><given-names>T.</given-names></name>
<name><surname>Grote</surname><given-names>M.</given-names></name>
<name><surname>Oppelt</surname><given-names>P.</given-names></name>
<name><surname>Franke</surname><given-names>U.</given-names></name>
<name><surname>Schaefers</surname><given-names>H. J.</given-names></name>
<name><surname>Wahlers</surname><given-names>T.</given-names></name>
</person-group><article-title>Impact of PAF antagonist BN 52021 (ginkolide B) on post-ischemic graft function in clinical lung transplantation</article-title><source>
<italic>The Journal of Heart and Lung Transplantation</italic>
</source><year>2001</year><volume>20</volume><issue>3</issue><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/S1053-2498(00)00226-6</pub-id><pub-id pub-id-type="other">2-s2.0-0035095157</pub-id><pub-id pub-id-type="pmid">11257563</pub-id>
</element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhainaut</surname><given-names>J. F.</given-names></name>
<name><surname>Tenaillon</surname><given-names>A.</given-names></name>
<name><surname>Le Tulzo</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group</article-title><source>
<italic>Critical Care Medicine</italic>
</source><year>1994</year><volume>22</volume><issue>11</issue><fpage>1720</fpage><lpage>1728</lpage><pub-id pub-id-type="pmid">7956274</pub-id>
</element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurihara</surname><given-names>K.</given-names></name>
<name><surname>Wardlaw</surname><given-names>A. J.</given-names></name>
<name><surname>Moqbel</surname><given-names>R.</given-names></name>
<name><surname>Kay</surname><given-names>A. B.</given-names></name>
</person-group><article-title>Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide- derived PAF antagonist, BN 52021</article-title><source>
<italic>The Journal of Allergy and Clinical Immunology</italic>
</source><year>1989</year><volume>83</volume><issue>1</issue><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0091-6749(89)90480-6</pub-id><pub-id pub-id-type="other">2-s2.0-0024586456</pub-id><pub-id pub-id-type="pmid">2536413</pub-id>
</element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montrucchio</surname><given-names>G.</given-names></name>
<name><surname>Alloatti</surname><given-names>G.</given-names></name>
<name><surname>Camussi</surname><given-names>G.</given-names></name>
</person-group><article-title>Role of platelet-activating factor in cardiovascular pathophysiology</article-title><source>
<italic>Physiological Reviews</italic>
</source><year>2000</year><volume>80</volume><issue>4</issue><fpage>1669</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1152/physrev.2000.80.4.1669</pub-id><pub-id pub-id-type="other">2-s2.0-0033771162</pub-id><pub-id pub-id-type="pmid">11015622</pub-id>
</element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for blocking neointimal formation after vascular injury</article-title><source>
<italic>Journal of the American Heart Association</italic>
</source><year>2017</year><volume>6</volume><issue>6</issue><pub-id pub-id-type="doi">10.1161/JAHA.117.005889</pub-id><pub-id pub-id-type="other">2-s2.0-85041756036</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Da</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>AGGF1 therapy inhibits thoracic aortic aneurysms by enhancing integrin <italic>&#x003b1;</italic>7-mediated inhibition of TGF-<italic>&#x003b2;</italic>1 maturation and ERK1/2 signaling</article-title><source>
<italic>Nature Communications</italic>
</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>p. 2265</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37809-x</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<name><surname>Qi</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>lncRNA NEAT1 downregulation ameliorates the myocardial infarction of mice by regulating the miR-582-5p/F2RL2 axis</article-title><source>
<italic>Cardiovascular Therapeutics</italic>
</source><year>2022</year><volume>2022</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1155/2022/4481360</pub-id><pub-id pub-id-type="publisher-id">4481360</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chacar</surname><given-names>S.</given-names></name>
<name><surname>Hajal</surname><given-names>J.</given-names></name>
<name><surname>Saliba</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Long-term intake of phenolic compounds attenuates age-related cardiac remodeling</article-title><source>
<italic>Aging Cell</italic>
</source><year>2019</year><volume>18</volume><issue>2, article e12894</issue><pub-id pub-id-type="doi">10.1111/acel.12894</pub-id><pub-id pub-id-type="other">2-s2.0-85062860260</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Dual roles of demethylation in cancer treatment and cardio-function recovery</article-title><source>
<italic>Redox Biology</italic>
</source><year>2023</year><volume>64, article 102785</volume><pub-id pub-id-type="doi">10.1016/j.redox.2023.102785</pub-id><pub-id pub-id-type="pmid">37343447</pub-id>
</element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>L.</given-names></name>
<name><surname>Dong</surname><given-names>C.</given-names></name>
<name><surname>Geng</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Ginkgolide B inactivates the NLRP3 inflammasome by promoting autophagic degradation to improve learning and memory impairment in Alzheimer's disease</article-title><source>
<italic>Metabolic Brain Disease</italic>
</source><year>2022</year><volume>37</volume><issue>2</issue><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s11011-021-00886-2</pub-id><pub-id pub-id-type="pmid">35050445</pub-id>
</element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Ginkgolide B targets and inhibits creatine kinase B to regulate the CCT/TRiC- SK1 axis and exerts pro-angiogenic activity in middle cerebral artery occlusion mice</article-title><source>
<italic>Pharmacological Research</italic>
</source><year>2022</year><volume>180, article 106240</volume><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106240</pub-id><pub-id pub-id-type="pmid">35513225</pub-id>
</element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roldan-Montero</surname><given-names>R.</given-names></name>
<name><surname>Perez-Saez</surname><given-names>J. M.</given-names></name>
<name><surname>Cerro-Pardo</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm</article-title><source>
<italic>Science Advances</italic>
</source><year>2022</year><volume>8</volume><issue>11, article eabm7322</issue><pub-id pub-id-type="doi">10.1126/sciadv.abm7322</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chakraborty</surname><given-names>R.</given-names></name>
<name><surname>Ostriker</surname><given-names>A. C.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Histone acetyltransferases p300 and CBP coordinate distinct chromatin remodeling programs in vascular smooth muscle plasticity</article-title><source>
<italic>Circulation</italic>
</source><year>2022</year><volume>145</volume><issue>23</issue><fpage>1720</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.057599</pub-id><pub-id pub-id-type="pmid">35502657</pub-id>
</element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>DP1 (prostaglandin D2 receptor 1) activation protects against vascular remodeling and vascular smooth muscle cell transition to myofibroblasts in angiotensin II-induced hypertension in mice</article-title><source>
<italic>Hypertension</italic>
</source><year>2022</year><volume>79</volume><issue>6</issue><fpage>1203</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.17584</pub-id><pub-id pub-id-type="pmid">35354317</pub-id>
</element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tripathi</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>B. K.</given-names></name>
<name><surname>Liehn</surname><given-names>E. A.</given-names></name>
<etal/>
</person-group><article-title>Caffeine prevents restenosis and inhibits vascular smooth muscle cell proliferation through the induction of autophagy</article-title><source>
<italic>Autophagy</italic>
</source><year>2022</year><volume>18</volume><issue>9</issue><fpage>2150</fpage><lpage>2160</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.2021494</pub-id><pub-id pub-id-type="pmid">35012409</pub-id>
</element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ostriker</surname><given-names>A. C.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Chakraborty</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>TET2 protects against vascular smooth muscle cell apoptosis and intimal thickening in transplant vasculopathy</article-title><source>
<italic>Circulation</italic>
</source><year>2021</year><volume>144</volume><issue>6</issue><fpage>455</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.050553</pub-id><pub-id pub-id-type="pmid">34111946</pub-id>
</element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mori</surname><given-names>Y.</given-names></name>
<name><surname>Gonzalez Medina</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Roles of vascular endothelial and smooth muscle cells in the vasculoprotective effect of insulin in a mouse model of restenosis</article-title><source>
<italic>Diabetes &#x00026; Vascular Disease Research</italic>
</source><year>2021</year><volume>18</volume><issue>3, article 147916412110273</issue><pub-id pub-id-type="doi">10.1177/14791641211027324</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fransvea</surname><given-names>E.</given-names></name>
<name><surname>Angelotti</surname><given-names>U.</given-names></name>
<name><surname>Antonaci</surname><given-names>S.</given-names></name>
<name><surname>Giannelli</surname><given-names>G.</given-names></name>
</person-group><article-title>Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells</article-title><source>
<italic>Hepatology</italic>
</source><year>2008</year><volume>47</volume><issue>5</issue><fpage>1557</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1002/hep.22201</pub-id><pub-id pub-id-type="other">2-s2.0-43949140575</pub-id><pub-id pub-id-type="pmid">18318443</pub-id>
</element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Peng</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Angiogenic factor AGGF1 blocks neointimal formation after vascular injury <italic>via</italic> interaction with integrin <italic>&#x003b1;</italic>7 on vascular smooth muscle cells</article-title><source>
<italic>The Journal of Biological Chemistry</italic>
</source><year>2022</year><volume>298</volume><issue>4, article 101759</issue><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101759</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>B.</given-names></name>
<name><surname>James</surname><given-names>S.</given-names></name>
<name><surname>Agewall</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)</article-title><source>
<italic>European Heart Journal</italic>
</source><year>2018</year><volume>392</volume><fpage>119</fpage><lpage>177</lpage></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Luo</surname><given-names>R.</given-names></name>
<name><surname>Guo</surname><given-names>G.</given-names></name>
</person-group><article-title>Development of innovative biomaterials and devices for the treatment of cardiovascular diseases</article-title><source>
<italic>Advanced Materials</italic>
</source><year>2022</year><volume>34</volume><issue>46, article e2201971</issue><pub-id pub-id-type="doi">10.1002/adma.202201971</pub-id></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li&#x000e9;nart</surname><given-names>S.</given-names></name>
<name><surname>Merceron</surname><given-names>R.</given-names></name>
<name><surname>Vanderaa</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Structural basis of latent TGF-<italic>&#x003b2;</italic>1 presentation and activation by GARP on human regulatory T cells</article-title><source>
<italic>Science</italic>
</source><year>2018</year><volume>362</volume><issue>6417</issue><fpage>952</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1126/science.aau2909</pub-id><pub-id pub-id-type="other">2-s2.0-85056824127</pub-id><pub-id pub-id-type="pmid">30361387</pub-id>
</element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diaz-Rodriguez</surname><given-names>S.</given-names></name>
<name><surname>Rasser</surname><given-names>C.</given-names></name>
<name><surname>Mesnier</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo</article-title><source>
<italic>European Heart Journal</italic>
</source><year>2021</year><volume>42</volume><issue>18</issue><fpage>1760</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab027</pub-id><pub-id pub-id-type="pmid">33580685</pub-id>
</element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Hernandez</surname><given-names>M.</given-names></name>
<name><surname>Gower</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>JAGGED-NOTCH3 signaling in vascular remodeling in pulmonary arterial hypertension</article-title><source>
<italic>Science Translational Medicine</italic>
</source><year>2022</year><volume>14</volume><issue>643, article eabl5471</issue><pub-id pub-id-type="doi">10.1126/scitranslmed.abl5471</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Cao</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension</article-title><source>
<italic>Respiratory Research</italic>
</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>p. 6</fpage><pub-id pub-id-type="doi">10.1186/s12931-022-01927-9</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>[Corrigendum] Astragaloside IV attenuates hypoxia-induced pulmonary vascular remodeling via the Notch signaling pathway</article-title><source>
<italic>Molecular Medicine Reports</italic>
</source><year>2021</year><volume>25</volume><issue>1</issue><pub-id pub-id-type="doi">10.3892/mmr.2021.12547</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Ren</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension</article-title><source>
<italic>Biomedicine &#x00026; Pharmacotherapy</italic>
</source><year>2019</year><volume>109</volume><fpage>1740</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.058</pub-id><pub-id pub-id-type="other">2-s2.0-85056792664</pub-id><pub-id pub-id-type="pmid">30551428</pub-id>
</element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA-24 attenuates vascular remodeling in diabetic rats through PI3K/Akt signaling pathway</article-title><source>
<italic>Nutrition, Metabolism, and Cardiovascular Diseases</italic>
</source><year>2019</year><volume>29</volume><issue>6</issue><fpage>621</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2019.03.002</pub-id><pub-id pub-id-type="other">2-s2.0-85064316402</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fan</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
</person-group><article-title>MicroRNA-24 attenuates diabetic vascular remodeling by suppressing the NLRP3/caspase&#x02011;1/IL&#x02011;1<italic>&#x003b2;</italic> signaling pathway</article-title><source>
<italic>International Journal of Molecular Medicine</italic>
</source><year>2020</year><volume>455</volume><fpage>1534</fpage><lpage>1542</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2020.4533</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>H.</given-names></name>
<name><surname>Zhai</surname><given-names>W.</given-names></name>
<name><surname>Zhong</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Nkx2-3 induces autophagy inhibiting proliferation and migration of vascular smooth muscle cells via AMPK/mTOR signaling pathway</article-title><source>
<italic>Journal of Cellular Physiology</italic>
</source><year>2021</year><volume>236</volume><issue>11</issue><fpage>7342</fpage><lpage>7355</lpage><pub-id pub-id-type="doi">10.1002/jcp.30400</pub-id><pub-id pub-id-type="pmid">33928642</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Ginkgolide B improves vascular remodeling and inflammation after vessel injury. (a) The schedule of animal experiment design. Collect blood from orbital venous plexus. (b) The detection of blood flow velocity by the Doppler echocardiography (<italic>n</italic> = 12 each group). The histological analysis performed using H&#x00026;E staining (c) and the corresponding quantification (e) and Masson's staining (d) and the corresponding quantification (f) (scar bar: 50&#x02009;<italic>&#x003bc;</italic>m; <italic>n</italic> = 4 each group). (g) The mRNA expression of <italic>Mcp1</italic> (monocyte chemoattractant protein 1), <italic>Cd68</italic> (cluster of differentiation 68), and <italic>&#x003b1;-Sma</italic> (<italic>&#x003b1;</italic>-smooth muscle actin) in tissues (<italic>n</italic> = 4 each group). All data are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus RCA treatment with vehicle; <sup>#</sup><italic>P</italic> &#x0003c; 0.05 versus LCA treatment with vehicle.</p></caption><graphic xlink:href="CDTP2023-8848808.001" position="float"/></fig><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Ginkgolide B plays a protective role in vascular injury by the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway. (a) The protein level detection of Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 and quantification <italic>in vivo</italic>. (b) The mRNA level detection of Pro-Tgf<italic>&#x003b2;</italic>1 <italic>in vivo</italic>. The ELISA detection of Tgf<italic>&#x003b2;</italic>1 (c), Mcp1 (d), and <italic>&#x003b1;</italic>-Sma (d) in serum. All data (<italic>n</italic> = 4 each group) are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus RCA treatment with vehicle; <sup>#</sup><italic>P</italic> &#x0003c; 0.05 versus LCA treatment with vehicle.</p></caption><graphic xlink:href="CDTP2023-8848808.002" position="float"/></fig><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Ginkgolide B has no influence of Tgf<italic>&#x003b2;</italic>1/Smad signal pathway in human umbilical vein endothelial cells (HUVECs). (a) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 in HUVECs stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 15&#x02009;min, 30&#x02009;min, and 60&#x02009;min (<italic>n</italic> = 4 each group). (b) The cell viability of HUVECs incubated with different concentrations of GB was detected by CCK8 (<italic>n</italic> = 8 each group). (c) The ELISA detection of Tgf<italic>&#x003b2;</italic>1 in cell culture supernatant (<italic>n</italic> = 4 each group). (d) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 in HUVECs stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min and then treated with GB for 2 hours (<italic>n</italic> = 4 each group). All data are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus control.</p></caption><graphic xlink:href="CDTP2023-8848808.003" position="float"/></fig><fig position="float" id="fig4"><label>Figure 4</label><caption><p>Ginkgolide B regulates the Tgf<italic>&#x003b2;</italic>1/Smad signal pathway in human vascular smooth muscle cells (HVSMAs). (a) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 in HVSMAs stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 15&#x02009;min, 30&#x02009;min, and 60&#x02009;min (<italic>n</italic> = 4 each group). (b) The cell viability of HVSMAs incubated with different concentrations of GB was detected by CCK8 (<italic>n</italic> = 8 each group). (c) The ELISA detection of Tgf<italic>&#x003b2;</italic>1 in cell culture supernatant (<italic>n</italic> = 4 each group). (d) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 in HVSMAs stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min and then treated with GB for 2 hours (<italic>n</italic> = 4 each group). All data are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus control.</p></caption><graphic xlink:href="CDTP2023-8848808.004" position="float"/></fig><fig position="float" id="fig5"><label>Figure 5</label><caption><p>The protective role of Ginkgolide B is abolished after incubated with Tgf<italic>&#x003b2;</italic>1 inhibitor in HVSMAs. (a) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 stimulated with different concentration of pirfenidone (PFD, Tgf<italic>&#x003b2;</italic>1 inhibitor). (b) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min and then treated with different concentration of pirfenidone. (c) The western blot analysis for Tgf<italic>&#x003b2;</italic>1 and p-Smad2/3 stimulated with 3&#x02009;ng/ml TGF-<italic>&#x003b2;</italic>1 for 60&#x02009;min and then treated with GB or pirfenidone for 2 hours. (d) The ELISA detection of Tgf<italic>&#x003b2;</italic>1 in cell culture supernatant. All data (<italic>n</italic> = 4 each group) are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus control; <sup>#</sup><italic>P</italic> &#x0003c; 0.05 versus treatment with TGF-<italic>&#x003b2;</italic>1; <sup>&#x00026;</sup><italic>P</italic> &#x0003c; 0.05 versus treatment with TGF-<italic>&#x003b2;</italic>1 and pirfenidone; <sup><italic>&#x003a6;</italic></sup><italic>P</italic> &#x0003c; 0.05 versus treatment with TGF-<italic>&#x003b2;</italic>1 and GB.</p></caption><graphic xlink:href="CDTP2023-8848808.005" position="float"/></fig><fig position="float" id="fig6"><label>Figure 6</label><caption><p>The protective function of Ginkgolide B in vessel remodeling and inflammation caused by vascular injury is vanished in Tgf<italic>&#x003b2;</italic>1 knockout mice. The mice were treated with pirfenidone capsules (presenting as PFD) and Yinxingneizhi Zhusheye (including Ginkgolide B) (presenting as GB). (a) The schedule of animal experiment design. Collect blood from orbital venous plexus. (b) The detection of blood flow velocity by the Doppler echocardiography and quantification (e) (<italic>n</italic> = 8 each group). The histological analysis performed using H&#x00026;E staining (c) and the corresponding quantification (f) and Masson's staining (d) and the corresponding quantification (g) (scar bar: 50&#x02009;<italic>&#x003bc;</italic>m; <italic>n</italic> = 4 each group). (h) The mRNA expression of <italic>Mcp1</italic>, <italic>Cd68</italic>, and <italic>&#x003b1;-Sma</italic> in tissues (<italic>n</italic> = 4 each group). All data are presented as mean &#x000b1; SEM. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 versus RCA treatment with vehicle.</p></caption><graphic xlink:href="CDTP2023-8848808.006" position="float"/></fig><fig position="float" id="fig7"><label>Figure 7</label><caption><p>The molecular docking of Ginkgolide B and Tgf<italic>&#x003b2;</italic>1. (a) 2D map. (b&#x02013;d) The different form of 3D map.</p></caption><graphic xlink:href="CDTP2023-8848808.007" position="float"/></fig><fig position="float" id="fig8"><label>Figure 8</label><caption><p>Molecular mechanism involved in vascular remodeling. Vessel injury as in the case of PCI causes Tgf<italic>&#x003b2;</italic>1, activates Smad2/3 phosphorylation, and contributes to the transcription of genes taken part in vascular remodeling. Ginkgolide B represses the production of Tgf<italic>&#x003b2;</italic>1, further reduces Smad2/3 phosphorylation, and contributes to the decline transcription of genes taken part in vascular remodeling, which could decrease restenosis and thrombosis.</p></caption><graphic xlink:href="CDTP2023-8848808.008" position="float"/></fig></floats-group></article>
